TIXAGEVIMAB/CILGAVIMAB – Storage and Stability

Tixagevimab/Cilgavimab [TIXA/CILGA], a combination of two recombinant long-acting monoclonal antibodies administered as two separate consecutive injections, may not be approved or authorized for use in your country. AstraZeneca is providing you with this material as an information service and professional courtesy. Providing this information does not constitute any recommendation for use.

For US only: EVUSHELD™ (tixagevimab co-packaged with cilgavimab) is not FDA-approved and is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of EVUSHELD under Section 564(b)(1) of the Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

TIXA/CILGA should be stored in a refrigerator at 2-8°C (36-46°F) in the original carton to protect from light.¹

Summary

- TIXA/CILGA should be stored in a refrigerator at 2-8°C (36-46°F) in the original carton to protect from light.¹
- AstraZeneca does not recommend TIXA/CILGA storage in any other manner than as described in the product information. The safety and efficacy of TIXA/CILGA cannot be assured if stored outside the recommended conditions.
- AstraZeneca cannot advise on the suitability to use the product if a temperature excursion occurred beyond the AstraZeneca distribution chain of control, as it is not possible to know the true circumstances of the excursion.

How the Product is Supplied

- TIXA/CILGA is supplied as individual single-dose vials of Tixagevimab and Cilgavimab which are co-packaged.¹
  - TIXA/CILGA is not provided in pre-filled syringes.
- The product is sterile and preservative-free with a pH of 6.0.¹
- The solutions for injection are clear to opalescent, colorless to slightly yellow, and practically free of visible particles.¹
- TIXA/CILGA contains Polysorbate-80 (a surfactant), which will cause foaming if shaken. This may interfere with withdrawal into the syringe and/or impact dose accuracy.²

Storage

Unopened Vial

- Store in refrigerator (2-8°C) for the duration of the product’s shelf life.¹
- Do not freeze or shake.¹
- Keep vials in original carton to protect from light.¹

Opened Vial

- Microbial challenge studies have not been performed as TIXA/CILGA is intended for single-use.³
- Prepared syringes should be administered immediately.¹
- If immediate administration is not possible, and the prepared syringes need to be stored, the following total cumulative storage time is applicable from vial puncture to the start of administration:
  - Refrigerated (2-8°C) and/or room temperature up to 25°C: In-use period of 4 hours.¹
- Vials may be exposed to light for the entire in-use period.²
- It is the responsibility of the customer to control and track cumulative storage and handling times.
Note: Region-specific health authorities or regulating bodies may further modify/restrict allowable in-use storage times due to potential logistical factors (e.g. tracking cumulative time and/or individual time at each temperature).

Temperature Excursions
It is the responsibility of the customer to control and monitor the temperature during transport, storage, and handling and for assessing the impact of any temperature excursions, should they occur, at any of these stages while the mAb drug product is under their ownership.

End-User Administration Site
- The temperature excursions described for unopened vials do not impact the allowable cumulative in-use times provided above.²
- Permitted temperature excursions do not include standard dose preparation and administration procedures.²
  - Once the stopper is punctured, temperature durations are defined by the dose preparation and administration instructions.
- Refer to the table below for information on allowable maximum duration of a single temperature excursion for Tixagevimab and Cilgavimab vials, from time of vial arrival at the end-user site (e.g. clinic).
  - This one-time excursion from refrigerated storage (2-8°C) is within stability limits for unopened vials.²

Table 1: Permitted temperature excursions at administration site.⁴

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Tixagevimab and Cilgavimab</th>
</tr>
</thead>
<tbody>
<tr>
<td>Temperature Range (°C)</td>
<td>0 to &lt;2</td>
</tr>
<tr>
<td>Unplanned single excursion</td>
<td>Maximum allowable duration of exposure (hours)</td>
</tr>
</tbody>
</table>

- Unopened vials must always be returned to refrigerated storage (2-8°C) following a permitted temperature excursion.²
  - Subsequent excursions are not permitted.
- AstraZeneca does not have end-user data to support the impact of an inadvertent temperature excursion on Tixagevimab and Cilgavimab stored below 0°C or above 40°C, therefore the affected product must be discarded.

Abbreviations:
mAbs: monoclonal antibodies; pH: power of hydrogen; TIXA/CILGA: Tixagevimab and Cilgavimab.

The information in this response is intended to be a concise summation of representative clinical trial data, rather than being all-inclusive, so all available published literature may not be included.

REFERENCE(S)

2. In House Data, AstraZeneca Pharmaceuticals LP. CMC E-mail communication. July 8, 2021.